Neurocrine Biosciences Fails to Meet Primary Endpoints in KINECT-DCP Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: NASDAQ.COM
- Clinical Trial Results: Neurocrine Biosciences' KINECT-DCP study failed to meet its primary and key secondary endpoints, indicating insufficient efficacy of valbenazine in treating pediatric and adult patients with dyskinetic cerebral palsy, which may impact the company's future R&D direction.
- Study Scale: This trial is the largest double-blind, placebo-controlled clinical study ever conducted in the field of dyskinetic cerebral palsy, lasting 14 weeks and assessing the efficacy, safety, and tolerability of valbenazine, revealing limited prospects for the drug in this indication.
- Safety Assessment: Despite the lack of efficacy, adverse events observed during the study were consistent with valbenazine's known safety profile, suggesting potential viability for the drug in other indications, which may support future market strategies.
- Market Reaction: Although the stock rose 1.74% to $147.53 during regular trading, it slipped 0.93% to $146.16 in after-hours trading, reflecting investor disappointment over the trial results, which could affect the company's short-term market performance.
NBIX
$147.53+Infinity%1D
Analyst Views on NBIX
Wall Street analysts forecast NBIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NBIX is 178.25 USD with a low forecast of 146.00 USD and a high forecast of 203.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
20 Buy
2 Hold
0 Sell
Strong Buy
Current: 145.000
Low
146.00
Averages
178.25
High
203.00
Current: 145.000
Low
146.00
Averages
178.25
High
203.00
About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
